Analysis of endogenous thrombin potential (ETP) in the plasma of COVID-19 patients showed that severe complications are associated with the development of resistance to the blood coagulation system inhibitor thrombomodulin (TM) [498]. The gene discussed is THBD; the disease is COVID-19.